Puma Biotechnology, Inc. — Q1 2012 Form 10-Q
Business context and reporting period. The filing covers the three months ended March 31, 2012. Puma was a development-stage biopharmaceutical company focused on cancer therapeutics and had generated no product revenue. Its licensed pipeline comprised oral and intravenous neratinib (PB272) and PB357, a potential backup compound. The statements reflect the accounting acquirer’s historical operations following the October 2011 reverse merger.
Key financial metrics
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | None | None reported |
| Research and development expense | $10.57 million | None |
| General and administrative expense | $1.23 million | $3,942 |
| Operating loss | $11.85 million | $3,942 |
| Net loss | $11.83 million | $3,942 |
| Net loss per share, basic and diluted | $0.59 | $0.001 |
| Cash used in operating activities | $2.78 million | $3,942 |
At March 31, cash and cash equivalents were $50.17 million, restricted cash was $1.05 million, working capital was $41.23 million, and stockholders’ equity was $42.60 million. Total liabilities were $10.23 million, mostly current; the filing reports no borrowings or debt balance. Current liabilities were $9.48 million, including $7.87 million accrued for licensor transition costs. No profit margins are meaningful because the company had no revenue.
Material changes versus the prior comparable period
- Operating expenses rose sharply as clinical development and operational activity ramped up; Q1 2011 had only nominal expenses and is not a like-for-like operating comparison.
- Q1 2012 R&D expense included approximately $8.16 million of outside clinical development services, primarily related to transferring trial responsibilities from the licensor. Management expected these transition-related costs to decrease significantly as duplicated work ended.
- Cash declined by $3.21 million during the quarter. Operating cash use was partly offset by an $8.90 million increase in accounts payable and accrued expenses, largely associated with transition activity.
- Accrued expenses increased from $0.50 million at year-end to $8.92 million at March 31, primarily because of the estimated licensor transition accrual.
Outlook, commentary, risks and unusual items
- Management expected cash on hand to fund anticipated expenditures for at least the next 12 months and clinical development through 2012 and into 2013. It estimated the next 12 months’ R&D spending at $20–25 million and G&A at $5–6 million.
- The company expected continuing losses and negative operating cash flow. It said additional financing would be needed thereafter, might be sought before 2013, and was not committed; unavailable or unfavorable financing could force delays or reductions in development and could dilute shareholders.
- Management said product approval was not expected until approximately 2015, assuming no unforeseen safety issues. Trial duration, cost, enrollment, manufacturing and regulatory requirements remain uncertain.
- A one-time approximately $0.4 million software installation and configuration cost was included in regulatory and quality-assurance R&D expense. The CEO’s warrant was revalued to approximately $7.44 million, producing an approximately $149,000 reduction in Q1 expense. Its valuation depends on assumptions and will be remeasured until its grant date is determined.
- The anti-dilutive warrants issued to 27 investors terminated unexercised after the stock began OTC trading on April 20, 2012, without a below-$3.75-per-share securities sale. The CEO also held a separate warrant intended to preserve at least 20% ownership under specified future-financing conditions.
- Shares traded on the OTC Bulletin Board and OTCQB, where the company warned of thin trading, volatility and difficulty selling shares. Management reported disclosure controls were effective at March 31, 2012; no pending or threatened legal proceedings were reported.
Important facts for investors to verify
- Whether the $7.87 million estimated licensor transition accrual is confirmed by actual costs, and how subsequent cash payments affect liquidity.
- Actual clinical-development spending, progress and enrollment for the three candidates compared with management’s cost and timing expectations.
- Cash burn and available financing as spending continues; management’s runway estimate is not a guarantee, and no committed financing sources were disclosed.
- The assumptions and future effects of the CEO warrant valuation, as well as potential dilution from outstanding options and any future equity financing.
- Whether OTC trading liquidity and share-price volatility materially affect investors’ ability to trade the stock.